Zoetis (ZTS) is back in focus after a wave of securities class action lawsuits and analyst downgrades followed the company’s disclosures about weaker veterinarian prescription trends, market share pressures, and lowered guidance.

Those concerns have been reflected in the price, with Zoetis shares at US$81.40 after a sharp fall in recent months, and the 1 year total shareholder return down 51.03%, indicating momentum has weakened despite a 5.80% 1 month share price rebound.

If this volatility has you looking beyond animal health, it could be a useful moment to scan for other growth stories using the 40 healthcare AI stocks.

With the stock down sharply over 1 year but trading at an indicated discount to some valuation and analyst estimates, the key question is whether Zoetis is now undervalued or if the share price already reflects slower future growth.

Most Popular Narrative: 12.4% Undervalued

According to a widely followed narrative from ValueInvestingSubstack, Zoetis is assessed with a fair value of $92.92 per share against the last close of $81.40, framing the current discount in the context of a slow but steady earnings profile.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword.

Read the complete narrative. Read the complete narrative.

Want to understand why a business with single digit growth still screens as undervalued here? The narrative leans on steady revenue expansion, disciplined margins, and an earnings multiple that assumes no heroics. Curious which long term profit and cash flow assumptions sit behind that $92.92 fair value and how they connect to the current P/E and forecast growth path? The full write up lays out those moving pieces clearly so you can judge the gap for yourself.

Result: Fair Value of $92.92 (UNDERVALUED)

However, there are clear pressure points, including the 11% revenue decline in US Companion Animal and rising generic competition, that could challenge the current undervalued narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Seen enough mixed signals to feel torn on Zoetis? Take a closer look at both sides of the story and weigh the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If Zoetis has prompted fresh questions about where to put your money to work next, broaden your watchlist now so you are not relying on one story.

• Target stability first by reviewing companies with stronger financial buffers and cash generation using the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for potential upside by scanning a curated set of 46 high quality undervalued stocks built around quality fundamentals and pricing anomalies.
• Spot early opportunities before the crowd by checking out a screener containing 20 high quality undiscovered gems that still fly under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.